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Abstract
Background:  Heterozygous mutations of MYH9, encoding the Non-Muscular Myosin Heavy
Chain-IIA (NMMHC-IIA), cause a complex disorder named MYH9-related disease, characterized by
a combination of different phenotypic features. At birth, patients present platelet macrocytosis,
thrombocytopenia and leukocyte inclusions containing NMMHC-IIA. Moreover, later in life some
of them develop the additional features of sensorineural hearing loss, cataracts and/or
glomerulonephritis that sometimes leads to end stage renal failure.
Results: To clarify the mechanism by which the mutant NMMHC-IIA could cause phenotypic
anomalies at the cellular level, we examined the effect of transfection of the full-length mutated
D1424H MYH9 cDNAs. We have observed, by confocal microscopy, abnormal distribution of the
protein and formation of rod-like aggregates reminiscent of the leukocyte inclusions found in
patients. Co-transfection of differently labeled wild-type and mutant full-length cDNAs showed the
simultaneous presence of both forms of the protein in the intracellular aggregates.
Conclusion: These findings suggest that the NMMHC-IIA mutated in position 1424 is able to
interact with the WT form in living cells, despite part of the mutant protein precipitates in non-
functional aggregates. Transfection of the entire WT or mutant MYH9 in cell lines represents a
powerful experimental model to investigate consequences of MYH9 mutations.
Background
Heterozygous mutations in the MYH9 gene, encoding the
Non-Muscle Myosin Heavy Chain IIA (NMMHC-IIA), are
responsible for the recently defined MYH9-related disease
(MYH9-RD) [1]. This entity includes clinical phenotypes
previously classified as distinct disorders: May-Hegglin
anomaly, Sebastian syndrome, Fechtner syndrome, and
Epstein syndrome. All patients present since birth throm-
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bocytopenia and leukocyte inclusions consisting of aggre-
gates of NMMHC-IIA. However, during infancy or adult
life many subjects develop the additional features of sen-
sorineural hearing loss, cataracts, and/or progressive
nephropathy leading to renal failure [1].
NMMHC-IIA is a conventional, non-sarcomeric myosin
expressed in most cells and tissues, where it is involved in
several functions including cytokinesis, cell motility, and
maintenance of cell shape [2]. The N-terminal portion of
NMMHC-IIA forms the myosin globular head, responsi-
ble for ATPase and actin-binding activity, while the C-ter-
minal tail region regulates both dimerization of heavy
chains in coiled-coil structures and association of myosin
molecules into functional filaments [2].
The mechanisms by which MYH9 mutations cause MYH9-
RD are poorly defined, and both haploinsufficiency and a
dominant-negative effect of the mutated protein have
been hypothesized [3-6]. In particular, studies on
NMMHC-IIA tail fragments demonstrated that differently
mutated proteins could interact to a different extent with
WT counterparts to exert a dominant-negative biochemi-
cal effect [5]. Nevertheless, investigations on megakaryo-
cytes and platelets from patients with MYH9-RD
suggested that mutant NMMHC-IIA proteins could not be
expressed in living cells, possibly because of their high
instability [3,6]. Difficulties in addressing these issues
include the unavailability of the entire NMMHC-IIA [7],
so that experimental approaches were so far limited to in
vitro studies on either N-terminal or C-terminal portions
of the molecule [5].
Here we present the results of transfection with the entire
NMMHC-IIA molecule both in wild-type (WT) and
mutated form (D1424H) in COS-7 and HeLa cell lines.
Methods
The full-length 5883 bp MYH9 cDNA was cloned using
the Gateway system (Invitrogen). RNA was extracted from
a lymphoblastoid cell line from a control individual. Five
hundred nanograms of total RNA were specifically retro-
transcribed in order to obtain MYH9 cDNA (Transcriptor
First Strand cDNA Synthesis Kit, Roche). The resulting
cDNA was used for PCR amplification. Primers, which





Forty nanograms of cDNA were used to amplify the entire
MYH9 coding sequence.
The PCR fragment was introduced into plasmid vector
pDONOR207 (Invitrogen) via the BP recombination
reaction, according to the recommendations of the manu-
facturer, to generate the entry clone. Control of the result-
ing cDNA was performed by complete sequencing.
Comparison of the sequence in our clone with the cDNA
reported in the NCBI database (NM_002473) did not
reveal any difference.
Site directed mutagenesis was performed using a commer-
cial kit (Quick Change, Stratagene) to introduce a G to C
transversion in position 4270, in order to obtain the
D1424H mutant. WT and D1424H constructs were then
used to perform LR recombination reactions with the
Gateway system compatible expression vector pcDNA3.1/
nV5-DEST (Invitrogen) and Gateway converted Flag vec-
tor to express N-terminally tagged V5, or Flag fusion pro-
teins, respectively. The integrity of all constructs was
confirmed by direct complete DNA sequencing.
COS-7 and HeLa cells were maintained in Dulbecco's
modified Eagle's medium supplemented with 10% (v/v)
fetal bovine serum (GibcoBRL), 2 mM L-glutamine, 100
U/ml penicillin, 100 μg/ml streptomycin at 37°C in a
humidified atmosphere with 5% CO2. Transfections of
both cell lines were performed using the Polyfect reagent
(Quiagen), according to the manufacturer's instructions,
on cells plated at 50–60% confluence and transfected at
an estimated 80–90% confluence after 24 h. Cells were
harvested 24, 48 and 72 hours after transfection and cyt-
ospun onto slides for immunofluorescence staining.
Standard peripheral blood smears were prepared from
two patients with MYH9-RD caused by D1424H substitu-
tion of NMMHC-IIA. Both patients have been already
reported [1]. The institutional review board of Fondazi-
one IRCCS Policlinico San Matteo, University of Pavia,
Italy, approved the study and patients gave written
informed consent to the study.
The following primary antibodies (Abs) were used: rabbit
polyclonal PR-B440P (Covance Research Products Berke-
ley, CA) recognizing the 12-residues sequence
(GKADGAEAKPAE) of the C-terminus of NMMHC-IIA
[8], mouse monoclonal NMG2 to a specific epitope of the
N-terminus of NMMHC-IIA (a kind gift of Dr Saverio Sar-
tore, Biomedical Sciences, University of Padua, Italy) [9];
rabbit polyclonal anti-flag (Sigma, St. Louis, MI), and
mouse monoclonal anti-V5 (Invitrogen).
Secondary antibodies were goat anti-mouse or anti-rabbit
conjugated with either Alexa Fluor 488 or Alexa Fluor 594
(Invitrogen). Confocal microscopy was performed
through the TCS SPII confocal laser scanning microscopy
system (Leica, Heidelberg, Germany), equipped with aPathoGenetics 2008, 1:5 http://www.pathogeneticsjournal.com/content/1/1/5
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Leica DM IRBE inverted microscope, as previously
described [6]. Confocal optical sections were performed
every 500 nm. Conventional fluorescence microscopy was
performed through an Axioscope 2 Plus microscope (Carl
Zeiss, Gottingen, Germany), as described [6].
Results and discussion
The entire 5883 bp MYH9 cDNAs, both WT and D1424H
form, have been transfected in COS-7 or in HeLa cell lines.
Immunofluorescence staining showed that COS-7 cells,
which constitutively do not express MYH9, expressed the
transfected WT or D1424H NMMHC-IIAs, and that the
signal of these molecules was stable for at least 72 hours
after transfection. No NMMHC-IIA signal has been
observed in non-transfected cells or in cells transfected
with the vector alone. Transfected COS-7 cells were simi-
larly labeled by antibodies specific either to the N-termi-
nus or to the C-terminus of the protein, demonstrating
that the entire WT or mutant NMMHC-IIA were expressed.
Confocal microscopy demonstrated that the signal of the
respective protein tags (V5 for WT, flag for D1424H) was
completely superimposable to the NMMHC-IIA signal,
confirming that staining for the tags was reliable to assess
both expression and intracellular distribution of the
respective exogenous NMMHC-IIAs (data not shown).
While in COS-7 transfected with WT MYH9 the NMMHC-
IIA signal was uniformly distributed in the cytoplasm, in
cells transfected with the D1424H construct NMMHC-IIA
formed rod-like protein aggregates similar to those
Transfection of D1424H MYH9 in COS-7 or HeLa cells results in the formation of NMMHC-IIA aggregates similar to those of  granulocytes of MYH9-RD patients carrying the same mutation Figure 1
Transfection of D1424H MYH9 in COS-7 or HeLa cells results in the formation of NMMHC-IIA aggregates sim-
ilar to those of granulocytes of MYH9-RD patients carrying the same mutation. A) COS-7 cells transfected with 
WT MYH9 cDNA. B) COS-7 cells transfected with D1424H MYH9 cDNA. C) HeLa cells transfected with D1424H MYH9 
cDNA. D) Staining of granulocyte from an unaffected individual. E) and F) Staining of granulocytes from patients with the 
D1424H substitution obtained by labeling the peripheral blood smears for NMMHC-IIA. Scale bars correspond to 10 μm. 
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observable in granulocytes of patients carrying the
D1424H substitution (Figure 1A and 1B). To show such
similarity, peripheral blood smears were prepared from
two patients with MYH9-RD caused by the D1424H sub-
stitution of NMMHC-IIA, compared with an unaffected
individual (Figure 1D–F). Both patients had already been
reported [1].
These aggregates of mutant NMMHC-IIA were present in
most transfected cells, and they were usually evident over
a diffuse cytoplasmic staining. When we transfected with
the same constructs HeLa cells, which constitutively
express NMMHC-IIA, we obtained the same results as in
COS-7 (Figure 1C).
Thus, transfection of the entire MYH9  mutant cDNA
reproduced in two different cell lines, independently from
their endogenous myosin expression, the NMMHC-IIA
aggregates that are typical of granulocytic cells in MYH9-
RD [1,4,10]. Interestingly, a similar distribution of
NMMHC-IIA was observed in tubular epithelia cells from
the only patient with MYH9-RD whose renal biopsy was
investigated by immunohystochemistry [10], suggesting
that this behavior of mutant NMMHC-IIA could be com-
mon to different cell types in vivo.
Since in cells of MYH9-RD patients both a WT and a
mutant allele are present, we co-transfected COS-7 or
HeLa cells with both WT and D1424H cDNAs and inves-
tigated intracellular localization of the two exogenous
NMMHC-IIAs by double-labeling cells for the respective
protein tags. In co-transfected cells the mutant NMMHC-
IIA showed a distribution similar to that observed in cells
transfected with mutant MYH9 alone, with part of the flag
signal diffused in the cytoplasm and part organized in
rod-like aggregates (Figure 2A). We noticed that aggre-
gates were less frequent than in cells transfected with
D1424H cDNA alone. Confocal analysis demonstrated
that the V5 (WT) signal presented a high degree of co-
localization with the flag (mutant) signal diffused in the
cytoplasm, thus suggesting that transfected WT and
D1424H molecules interacted in these cells (Figure 2A–
C). Interestingly, the V5 signal was detected also at the
level of some of the aggregates disclosed by the flag reac-
tion, although it was less intense than the mutant signal
(Figure 2A–C). This finding indicates that rod-like aggre-
gates were mainly constituted by D1424H NMMHC-IIA,
although WT protein was trapped into some of these
structures. This observation is consistent with results pre-
viously obtained in granulocytes of patients with non-
Exogenous D1424H and WT NMMHC-IIA co-localize in co-transfected COS-7 cells Figure 2
Exogenous D1424H and WT NMMHC-IIA co-localize in co-transfected COS-7 cells. A) COS-7 cells co-transfected 
with both D1424H and WT MYH9 cDNAs tagged at the N-terminal end with flag and V5 epitopes, respectively: red staining 
for the flag epitope (mutant). B) Same co-transfected cells for the V5 epitope (WT, green). C) Merging of images resulting from 
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sense or frameshift MYH9  mutations resulting in a
truncated NMMHC-IIA [4,6,11].
Results of cotransfection similar to those in COS-7 cells
were also obtained in HeLa cells (not shown).
Conclusion
These findings suggest that the NMMHC-IIA mutated in
position 1424 is able to interact with the WT form in liv-
ing cells, despite part of the mutant protein precipitates in
non-functional aggregates. This observation is consistent
with previous studies on an in vitro model, which demon-
strated that the D1424N C-terminal fragment of
NMMHC-IIA, when mixed with its WT counterpart, is able
to form paracrystalline assemblies similar to those of the
WT/WT interaction [5]. The fact that NMMHC-IIA
mutated in position 1424 retains the ability to interact
with WT protein represents the basis for it to exert a dom-
inant-negative biochemical effect on the normal protein.
Transfection of the entire WT or mutant MYH9 in cell
lines represents a promising experimental model to inves-
tigate consequences of MYH9 mutations in cells.
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